Lancet Public Health最新文献

{"title":"Reviving action on child health—now!","authors":"","doi":"10.1016/s2468-2667(25)00102-1","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00102-1","url":null,"abstract":"Halving under-5 mortality within a generation has been the most spectacular success in health during modern times. The child survival movement of the Millennium Development Goal era (2000–15) unlocked levels of political commitment and new investment never before seen in women's and children's health. Why? Because a remarkable coalition was built between civil society, scientists, policy makers, and politicians. That alliance directly connected the evidence about what works to save children's lives to decision making. Politicians had the confidence—because they had the data—to invest in children, knowing that would yield rich rewards. Shockingly, this acceleration in progress is now under threat.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"71 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cigarette taxation reduces inequalities in child mortality","authors":"Garima Bhatt, Kamran Siddiqi","doi":"10.1016/s2468-2667(25)00090-8","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00090-8","url":null,"abstract":"In <em>The Lancet Public Health</em>, Olivia Bannon and colleagues<span><span>¹</span></span> provide empirical data to show the distinctive advantage of tobacco taxes in saving children's lives and reducing health inequalities. The authors found that substantial tax increases on cigarettes reduce mortality in children younger than 5 years (hereafter referred to as under-5 mortality), with the poorest quintile benefiting the most. However, smaller 10 percentage point increases were not associated with a significant difference between wealth quintiles. Furthermore, only specific taxes (based on quantity or weight-based taxes) were associated with reduced socioeconomic inequalities in under-5 child mortality, and not ad valorem taxes, which allow price adjustments to maintain affordability.<span><span>¹</span></span> The study also shows the value in investing in data infrastructure that can be reliably used to inform public health policies.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"55 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cigarette taxation and socioeconomic inequalities in under-5 mortality across 94 low-income and middle-income countries: a longitudinal ecological study","authors":"Olivia S Bannon, Jasper V Been, Sam Harper, Anthony A Laverty, Christopher Millett, Frank J van Lenthe, Filippos T Filippidis, Márta K Radó","doi":"10.1016/s2468-2667(25)00065-9","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00065-9","url":null,"abstract":"<h3>Background</h3>Although increasing cigarette taxes is known to improve child survival, there are few data on their effect on socioeconomic inequalities in child mortality. We investigated the association between cigarette taxation and socioeconomic inequalities in mortality in children younger than 5 years (hereafter referred to as under-5 mortality) in low-income and middle-income countries (LMICs).<h3>Methods</h3>This was a longitudinal ecological study. We linked country-level annual data on 94 LMICs, as defined by the World Bank, and annual data on under-5 mortality by wealth quintile from the UN Inter-agency Group for Child Mortality Estimation from 2008 to 2020. We used fixed-effect panel regression models to assess the association of cigarette taxes with absolute and relative inequalities in under-5 mortality by wealth quintile.<h3>Findings</h3>Increasing total cigarette tax by 10-percentage-points was associated with reduced under-5 mortality rates in all wealth quintiles. Raising total cigarette tax from 0·0–24·9% to 25·0–74·9% and 75·0% or more of their total retail value was associated with 3·8% (95% CI 0·2 to 7·3) and 7·6% (1·4 to 13·4) decreases in absolute inequality in under-5 mortality, respectively. This finding was mainly attributable to specific tax, which was associated with a 1·4% (0·3 to 2·6) reduction in absolute inequality for each 10-percentage-point increase. We estimated that raising total cigarette taxes to 75·0% or more in all 94 LMICs could have averted 281 017 (196 916 to 362 301) under-5 deaths in 2021.<h3>Interpretation</h3>High cigarette taxes are associated with a large decrease in absolute inequality in child mortality in LMICs. These findings support raising cigarette taxes to the WHO-recommended 75% or more of the retail value to protect the poorest children.<h3>Funding</h3>Swedish Research Council for Health, Working Life, and Welfare; Stiftelsen Riksbankens Jubileumsfond; European Union's Horizon 2020 Research and Innovation; and UK National Institute for Health and Care Research.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"36 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic costs of neurological and mental health care: implications for research and policy action","authors":"Crick Lund, Donela Besada","doi":"10.1016/s2468-2667(25)00094-5","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00094-5","url":null,"abstract":"No Abstract","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"70 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143889440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social prescribing in the USA: emerging learning and opportunities","authors":"Rachel Marshall, Alexandra Bradbury, Nicole Morgan, Katrina Pineda, Daniel Hayes, Alexandra Burton, Jill Sonke, Daisy Fancourt","doi":"10.1016/s2468-2667(25)00066-0","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00066-0","url":null,"abstract":"The global prevalence of chronic diseases and high costs of health care are complex challenges that are driving countries to focus on addressing the social determinants of health and downstream social needs. These challenges require innovative health-care practices that integrate disease prevention, treatment, and management with salutogenic initiatives to promote population health. Many countries have turned to social prescribing as a promising approach. Social prescribing connects people with non-clinical support and services within their communities. While social prescribing has more commonly been adopted in countries with government-funded national health services, in this Viewpoint, we share learning from examples in the USA. We argue that social prescribing in the USA is unique given the heterogeneity of the country and its health systems, and that this aspect influences programme activities, target-populations, and models. These examples offer valuable lessons about the barriers and enablers to implementing social prescribing in different contexts, including privatised health-care systems. Ultimately, we call upon US stakeholders to recognise the benefits that social prescribing could bring to public health and take action to support its development. We also invite stakeholders from other countries to consider learnings from the USA and how social prescribing can be successfully implemented in their contexts.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"6 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143872819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health impact and economic evaluation of the Expanded Program on Immunization in China from 1974 to 2024: a modelling study","authors":"Chaofan Wang, Xiaozhen Lai, Kaja Abbas, Koen B Pouwels, Haijun Zhang, Mark Jit, Hai Fang","doi":"10.1016/s2468-2667(25)00039-8","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00039-8","url":null,"abstract":"<h3>Background</h3>The Expanded Program on Immunization (EPI), initiated by WHO in 1974, is a cornerstone of public health. China's EPI covers more than a sixth of the world's population and includes eight routine vaccines with high coverage rates. This study aimed to estimate health and economic impacts of China's EPI over the past 50 years (1974–2024).<h3>Methods</h3>This study mathematically modelled the impact of all eight routine vaccines in China's EPI against eight pathogens (measles, pertussis, hepatitis B, tuberculosis, hepatitis A, Japanese encephalitis, meningitis A, and poliomyelitis) based on data availability and their substantial disease burden, particularly accounting for non-linearities in vaccine impact. Health and economic outcomes were determined using mathematical models between a counterfactual scenario without vaccination (vaccine coverage set to zero) and the current vaccination scenario (routine vaccination scheduled at age 0–6 years), based on calendar year and birth cohort approaches. The health impact of China's EPI from 1974 to 2024 was measured in the number of cases, deaths, and disability-adjusted life-years (DALYs) averted.<h3>Findings</h3>We estimated that China's EPI averted 703·02 million cases (95% credible interval 699·51–722·80) and 2·48 million deaths (2·14–2·97) in 1974–2024 based on the calendar year approach, equivalent to averting an estimated 160·22 million DALYs (145·05–196·99). Using the birth cohort approach, we predicted 707·41 million cases (703·93–727·03) and 7·01 million deaths (6·95–7·87) averted over the lifetime, corresponding to 279·02 million DALYs (265·78–316·12). From a societal perspective, the aggregated cost of vaccination was estimated to be US$124·06 billion (120·49–127·49), although the benefits amounted to $2417·85 billion (2359·38–2710·35). China's EPI yielded an aggregate benefit–cost ratio of 19·48 (18·82–22·08) from the societal perspective and 8·02 (7·64–8·80) from the provider's perspective.<h3>Interpretation</h3>China's EPI has shown remarkable health and economic achievements, contributing to worldwide EPI success in the past 50 years. Further investment in EPI is warranted to sustain coverage and expand vaccine inclusion in China and globally.<h3>Funding</h3>Beijing Natural Science Foundation.<h3>Translation</h3>For the Chinese translation of the abstract see Supplementary Materials section.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"261 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143866434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the effects of prescribed safer opioid supply and methadone in Ontario, Canada: a population-based matched cohort study","authors":"Tara Gomes, Daniel McCormack, Gillian Kolla, Samantha Young, Ahmed M Bayoumi, Ashley Smoke, Ping Li, Tony Antoniou","doi":"10.1016/s2468-2667(25)00070-2","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00070-2","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Prescribed safer opioid supply (SOS) programmes are novel harm reduction interventions. We examined health outcomes among people receiving SOS over time and relative to a similar group of people receiving methadone.&lt;h3&gt;Methods&lt;/h3&gt;We conducted a population-based cohort study among new SOS and methadone recipients in Ontario, Canada, who commenced treatment between Jan 1, 2016 and Dec 31, 2021. People receiving SOS were matched (1:1) to new methadone recipients based on age (within 3 years), sex, location of residence (public health unit), and propensity score (within 0·2 SDs). Primary outcomes were hospital-treated opioid-related toxicities, emergency department visits and inpatient hospitalisations, incident infections, and health-care costs (in CA$, excluding costs related to primary care services and medications) over 1 year of follow-up. Outcome rates were calculated over the follow-up period, with censoring on death, discontinuation of SOS or methadone, or end of follow-up (360 days). Within-group changes in outcomes were assessed using interrupted time-series analysis, and Prentice–Williams–Peterson regression was used to assess between-group differences in recurrent events.&lt;h3&gt;Findings&lt;/h3&gt;Of the 991 new recipients prescribed SOS and 25 116 new methadone recipients who met the eligibility criteria, 856 (86·4%) people receiving SOS were matched to 856 people receiving methadone. In the within-group analysis, matched SOS recipients had significant improvements in the monthly rate of opioid toxicities (step change –1·09 events per 100 individuals [95% CI –2·12 to –0·07]; p=0·037), all-cause emergency department visits (–8·85 per person-year [–13·5 to –4·20]; p=0·0002), all-cause inpatient hospitalisations (–2·08 per person-year [–3·41 to –0·75]; p=0·0022), incident infections (–0·68 per person-year [–1·22 to –0·14]; p=0·013), and non-primary-care-related health-care costs (–$91 699 per person-year [–112 749 to –70 650]; p&lt;0·0001). Results were consistent for methadone recipients. In the between-group analysis, individuals commencing SOS had significantly higher hazards of opioid toxicity (hazard ratio 2·83 [95% CI 1·97 to 4·06]), emergency department visits (1·16 [1·05 to 1·29]), and inpatient admissions (1·50 [1·13 to 1·99]), no significant difference in the rate of incident infection (1·51 [0·87 to 2·61]), and were less likely to discontinue treatment than those commencing methadone (0·62 [0·55 to 0·70]). When treatment discontinuation was removed as a censoring criterion, we found no difference between groups in the hazard of any of the primary outcomes except opioid toxicity (1·65 [1·38 to 1·97]).&lt;h3&gt;Interpretation&lt;/h3&gt;SOS and methadone were associated with improvements in health outcomes, including reduced opioid toxicities and health-care use, in the year after treatment initiation. The findings suggest SOS programmes play an important, complementary role to traditional opioid agonist treatment in expanding the opt","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"45 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143862268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in alcohol-specific deaths in England, 2001–22: an observational study","authors":"Melissa Oldham, Sarah Jackson, Jamie Brown, Vera Buss, Gautam Mehta, Jennifer Beam Dowd, John Holmes, Colin Angus","doi":"10.1016/s2468-2667(25)00047-7","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00047-7","url":null,"abstract":"<h3>Background</h3>Following the COVID-19 pandemic, many countries saw large increases in rates of alcohol-specific deaths, including England. This study aimed to examine whether there have been changes in the characteristics of those dying by specific cause of death, age, sex, and area-level deprivation.<h3>Methods</h3>Using annual mortality data in England published by the Office for National Statistics, we describe the prevalence and 95% CI of age-standardised rates of alcohol-specific deaths overall and by age, sex, area-level deprivation measured by quintiles of the Index of Multiple Deprivation (IMD), and cause of death between 2001 and 2022. We also compared demographic profiles of those dying before the COVID-19 pandemic (2017–19) and after (2020–22); calculated crude absolute differences in rates and relative rate ratios across age, sex, and IMD; and used a multivariable Poisson regression model to calculate the rate ratio and adjusted absolute differences for deaths by IMD quintile for each period, adjusting for age and sex.<h3>Findings</h3>Age-standardised rates of alcohol-specific deaths in England remained largely unchanged until 2019, before rising sharply by 19·4% in 2020 and continuing to rise by a further 13·5% to the highest level on record in 2022: 14·7 (95% CI 14·4–15·0) per 100 000 people. There were few relative demographic changes in alcohol-specific mortality between 2017–19 (pre-pandemic) and 2020–22 (after the start of the COVID-19 pandemic) because the largest absolute increases in alcohol-specific mortality were seen among groups that had the highest pre-pandemic rates, including men (absolute rate increase, 3·87; relative increase, 25·9%) and those from areas of higher deprivation (absolute rate increase, 4·72; relative increase, 22·5%). When examining causes of deaths, the largest absolute increase was in alcohol-related liver disease (2·37; relative increase, 27·2%), with the largest relative increase in acute causes (absolute rate increase, 0·49; relative increase, 35·4%), although these accounted for a smaller proportion of deaths compared to alcohol-related liver disease. There was little to no change in deaths from alcohol dependence syndrome (absolute rate increase, 0·02; relative increase, 5·8%).<h3>Interpretation</h3>Alcohol-specific deaths in England remain high and increased after the COVID-19 pandemic. Policies should aim to reduce rates of alcohol consumption at the population level. Substantial investment is also required to facilitate early detection of liver disease and effective treatment.<h3>Funding</h3>Cancer Research UK","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"26 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing public health policy to tackle alcohol-related harms","authors":"Pojsakorn Danpanichkul, Karn Wijarnpreecha","doi":"10.1016/s2468-2667(25)00048-9","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00048-9","url":null,"abstract":"The Global Burden of Disease Study 2021 identifies alcohol consumption as one of the top ten leading risk factors for disability.<span><span>¹</span></span> The COVID-19 pandemic has substantially affected public health, including shifts in alcohol-related mortality trends. Melissa Oldham and colleagues<span><span>²</span></span> critically examine alcohol-specific deaths in England over the past two decades, revealing a sharp increase since 2020. The most pronounced absolute rises were seen among men (absolute rate increase, 3·87; relative increase, 25·9%) and those from socioeconomically disadvantaged areas (absolute rate increase, 4·72; relative increase, 22·5%), exacerbating existing health inequalities and underscoring the need for targeted policy responses.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"4 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of extending PrEP initiation to primary care settings: a nationwide cohort study in France","authors":"Sophie Bamouni, Sophie Billioti de Gage, David Desplas, Julie Valbousquet, Julie Lamant, Jean-Philippe Joseph, François Dabis, Agnès Viot, Mojgan Hessamfar, Salim Fakir, Rosemary Dray-Spira, Michel Carles","doi":"10.1016/s2468-2667(25)00062-3","DOIUrl":"https://doi.org/10.1016/s2468-2667(25)00062-3","url":null,"abstract":"<h3>Background</h3>Pre-exposure prophylaxis (PrEP) medicines are key to reducing HIV infection. Improving access, increasing initiation, and expanding the populations covered is therefore important. In June, 2021, in France, PrEP initiation was extended to primary care. The aim of this study was to describe the deployment and characteristics of PrEP initiation in primary care.<h3>Methods</h3>We did a nationwide cohort study using data obtained from the French National Health Data System (Système National des Données de Santé). We included all people aged 15 years or older, who initiated PrEP in primary care between June 1, 2021, and Dec 31, 2022. We estimated the number of PrEP initiations per month over the period, and the characteristics of people initiating PrEP and prescribers, and PrEP use.<h3>Findings</h3>13 500 individuals initiated PrEP in primary care during the study period. The mean number of PrEP initiations increased from 654 (SD 64) per month between July and December, 2021, to 783 (SD 86) per month between July and December, 2022. Individuals initiating PrEP were predominantly male (12 996 [96·3%] of 13 500 individuals) with a mean age of 36 years (SD 11·8), who lived in large urban areas (9581 [71·0%]). 1012 (7·5%) of 13 500 individuals were socioeconomically disadvantaged. Of the 5125 PrEP initiation prescribers, 4542 (88·6%) were general practitioners (GPs), and 4713 (44·7%) of 10 525 were the patient's family practitioner. In the 6 months after PrEP initiation, 6216 (70·8%) of 8783 PrEP initiators had at least one monthly renewal (mean 3·3 renewals [SD 1·7]). 11 961 (82·4%) of 14 507 renewals were made by the same practitioner who had initiated PrEP, and this proportion was higher when the prescriber who had initiated PrEP was the family practitioner (6225 [92·5%] of 7135 renewals).<h3>Interpretation</h3>Although the number of PrEP initiations in primary care steadily increased over the study period, the profile of users was unchanged when compared with before extension. The high proportion of PrEP initiations not prescribed by family practitioners highlights potential barriers to sharing sexual health concerns with the family practitioner. Extending PrEP to women, individuals who are socioeconomically disadvantaged, and all those who might benefit from it will require increased awareness among target audiences and practitioners.<h3>Funding</h3>French National Agency for Medicines and Health Products Safety.","PeriodicalId":56027,"journal":{"name":"Lancet Public Health","volume":"183 1","pages":""},"PeriodicalIF":50.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}